University Medical Center Utrecht-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2021

  1. Dupilumab provides significant clinical benefit in a phase 3 trial in adolescents with uncontrolled atopic dermatitis irrespective of prior systemic immunosuppressant use

    Acta Dermato-Venereologica, Vol. 101, Núm. 7